1. Generics Bulletin
  2. >>Business
  3. >>Strategy

The Generics Bulletin Podcast: Teva, Sandoz, Sawai and US Orange Book patents

Editorial Team Discusses Strategic Moves By Major Players And US Patent Listing Debate

 
• By Dave Wallace

Generics Bulletin’s editorial team discusses the latest strategic developments for major industry players Teva, Sandoz and Sawai, as well as explaining the recent debate over US patent listings in the FDA’s Orange Book.

Generic Bulletin Podcast

This edition of the Generics Bulletin podcast sees editor Dave Wallace, deputy editor Dean Rudge and reporters Urtė Fultinavičiūtė and Adam Zamecnik discuss recent strategic moves for Teva, Sandoz and Sawai as well as controversy over US patent listings in the US Food and Drug Administration’s Orange Book.

Citeline · The Generics Bulletin Podcast: Teva, Sandoz, Sawai and US Orange Book patents

Open Media

Generics Bulletin previously covered the latest developments in Teva’s strategy in an in-depth article. (Also see "A Year After ‘Pivot To Growth’, Teva Keeps Pushing Forward With Innovative Assets" - Generics Bulletin, 13 May, 2024.)

We also previously covered Sandoz’s most recent strategic moves in biosimilars. (Also see "Sandoz ‘Surfs The Biosimilars Wave’ Despite US Natalizumab Delay" - Generics Bulletin, 8 May, 2024.)

Sawai recently reported its annual results for its financial year ended 31 March. (Also see "Sawai Narrowly Misses Annual Sales Forecast For 2023" - Generics Bulletin, 21 May, 2024.)

And a recent study shed light on US patents filed after FDA approval. (Also see "Majority Of US Patent Thickets Filed Post-FDA Approval, Study Finds" - Generics Bulletin, 16 May, 2024.)

More from Strategy

Celltrion Plans Multiple US Biosimilar Launches In An ‘Exciting And Momentous’ Year

 
• By Dave Wallace

With Celltrion having just received approval for its US Actemra (tocilizumab) biosimilar and having just launched its ustekinumab rival to Stelara – and with the introduction of the Korean developer’s denosumab rivals to Prolia and Xgeva just around the corner – 2025 is set to be a busy year, Celltrion USA chief commercial officer Thomas Nusbickel tells Generics Bulletin.

Alvotech Reveals Ramp-Up In Development As Sales Explode In 2024

 
• By Dave Wallace

With sales and profits shooting up in 2024, Alvotech has revealed plans to rapidly accelerate development to add between four and six programs to its pipeline of biosimilars every year, while at the same time unveiling details of several new brands that it will be seeking to challenge. The firm has also set out longer-term financial targets that anticipate more than trebling its revenues in the next three years.

Dr Reddy’s Bags Rights To Two More Biosimilars In Deal With Bio-Thera

 
• By Dave Wallace

India’s Dr Reddy’s and China’s Bio-Thera have struck a deal covering ustekinumab and golimumab biosimilars in multiple markets in south-east Asia.

Alvotech And Advanz Make First Omalizumab Filing

 
• By Dave Wallace

Alvotech and Advanz have announced a UK MHRA filing acceptance for their partnered AVT23 proposed biosimilar to Xolair (omalizumab).

More from Business

Alvotech And Advanz Make First Omalizumab Filing

 
• By Dave Wallace

Alvotech and Advanz have announced a UK MHRA filing acceptance for their partnered AVT23 proposed biosimilar to Xolair (omalizumab).

Hyloris Closes A Dramatic 2024 With A Move Towards Profit

 
• By Adam Zamecnik

After announcing updates in its ongoing legal battle and a leadership shakeup earlier this fiscal year, Hyloris closed 2024 with a slight rise in revenue and a shrinking of its reported net loss.

Cipla Becomes Formosa’s Latest Clobetasol Partner With 11-Country Deal

 
• By Dean Rudge

Cipla has bolstered its ophthalmology portfolio and increased its global offering after chalking up an agreement to add Formosa Pharmaceuticals’ USFDA-approved clobetasol propionate 0.05% ophthalmic suspension.